10 results on '"Aguadé Bruix S"'
Search Results
2. [Diagnosis of coronary disease by means of stress gamma-tomography with 99m-technetium-isonitriles]
- Author
-
Santana Boado C, Candell Riera J, Castell Conesa J, Amparo Garcia-Burillo, Olona M, Palet J, Aguadé Bruix S, Fraile M, Ortega-Alcalde D, and Soler-Soler J
- Subjects
Male ,Technetium Tc 99m Sestamibi ,Tomography, Emission-Computed, Single-Photon ,Exercise Test ,Humans ,Coronary Disease ,Female ,Middle Aged - Abstract
To assess the yield of exercise myocardial stress tomogammagraphy (SPET) with methoxy-isobutyl-isonitrile-technetium-99m (99mTc-MIBI) in the diagnosis of coronary artery disease.Seventy-two consecutive patients, without previous myocardial infarction and with coronary angiography, were investigated. All underwent a symptom-limited exercise test with intravenous infection of 15 mCi of 99mTc-MIBI 30-60 seconds before the end of exercise. Detection of tomographic images was performed after one hour. Rest images were detected 24 hours later. Images with exercise perfusion defects which became normal at rest were considered as positive.Sensitivity (84%), specificity (93%), global value (87%), positive predictive value (95%), and negative predictive value (79%) of 99mTc-MIBI were significantly higher than those of conventional exercise electrocardiogram (46%, 69%, 55%, 69% and 46%, respectively). These values were lower when exercise test was insufficient (peak heart rate below 80% in the absence of angina). The sensitivity values were similar for the diagnosis of one (81%), two (76%), and three (93%) vessel disease. The application of Bayes' theorem disclosed that the highest yield of MIBI was achieved with prevalences ranging between 30% and 70%.The efficacy of 99mTc-MIBI SPET for the diagnosis of coronary artery disease was satisfactory, particularly when exercise was sufficient and with a prevalence of coronary artery disease ranging between 30% and 70%.
3. [Influence of ergometric parameters on the results of myocardial perfusion tomographic scintigraphy]
- Author
-
Santana-Boado C, Candell-Riera J, Castell-Conesa J, Olona M, Palet-Balart J, Aguadé-Bruix S, Amparo Garcia-Burillo, Ortega-Alcalde D, Fm, Domènech-Torné, and Soler-Soler J
- Subjects
Male ,Technetium Tc 99m Sestamibi ,Tomography, Emission-Computed, Single-Photon ,Contrast Media ,Blood Pressure ,Coronary Disease ,Middle Aged ,Coronary Angiography ,Sensitivity and Specificity ,Heart Rate ,Exercise Test ,Humans ,Female ,Aged ,Retrospective Studies - Abstract
The percentage of peak predicted heart rate that is accepted to consider as sufficient a given exercise test is 85%. However, the optimal value of such rate and other exercise parameters for the purposes of myocardial single-photon emission tomography is not well established.With the aim of establishing the minimal levels of maximal heart rate, product heart rate x systolic blood pressure and ventilatory oxygen uptake to obtain an adequate diagnostic efficacy of myocardial perfusion scintigraphy, 159 patients with coronary artery disease or suspicion of this without previous myocardial infarction were studied with stress test single photon emission tomography with 99mTc-methoxi-isobutil-isonitrile. All the patients were coronary angiography tested.Sensitivity and negative predictive value were significantly higher at levels of heart rate80% (93 vs 78%; p = 0.002 and 94 vs 56%; p = 0.0004), product heart rate x systolic blood pressure18,000 (88 vs 78%; p = 0.04 and 84 vs 52%; p = 0.004) and5 METs (85 vs 77%; p = 0.002 and 74 vs 69%; p = 0.03).Sensitivity and negative predictive value of stress test single photon emission tomography with 99mTc-methoxi-isobutil-isonitrile are low if levels higher than 80% of heart rate, 18,000 of product of heart rate x systolic blood pressure and 5 METs have not been achieved.
4. Myocardial SPET in Hypertrophic Cardiomyopathy | Tomogammagrafía miocárdica de esfuerzo en los pacientes con miocardiopatía hipertrófica
- Author
-
Romero-Farina, G., Candell-Riera, J., Pereztol-Valdés, O., Aguadé-Bruix, S., Joan Castell-Conesa, Armadans, L., Reina, D., Galve, E., Palet, J., and Soler-Soler, J.
5. Diagnostic accuracy of technetium-99m-MIBI myocardial SPECT in women and men
- Author
-
Santana-Boado C, Candell-Riera J, Castell-Conesa J, Aguadé-Bruix S, Amparo Garcia-Burillo, Canela T, Jm, González, Cortadellas J, Ortega D, and Soler-Soler J
- Subjects
Male ,Technetium Tc 99m Sestamibi ,Tomography, Emission-Computed, Single-Photon ,Cardiac Catheterization ,Vasodilator Agents ,Coronary Disease ,Heart ,Dipyridamole ,Middle Aged ,Coronary Angiography ,Sensitivity and Specificity ,Predictive Value of Tests ,Case-Control Studies ,Exercise Test ,Humans ,Female ,Radiopharmaceuticals - Abstract
Noninvasive diagnosis of coronary artery disease in women has some limitations due to a higher percentage of false-positive results. In addition, a lower prevalence of disease can be observed in this population. In this study, we evaluated the diagnostic accuracy of 99mTc-methoxy-isobutyl-isonitrile (MIBI) SPECT in women and men, in a group of patients with proven coronary artery disease by coronary angiography (select minority) and in all patients where a noninvasive test (silent majority) was performed.Seven hundred and two consecutive patients without previous myocardial infarction were studied with 99mTc-MIBI myocardial SPECT. One hundred sixty-three patients had coronary angiography (select minority) and 539 did not (silent majority). All patients underwent exercise stress testing, and simultaneous dipyridamole was administered in 32% of patients who did not achieve maximum predicted heart rates. Diagnostic accuracy of the test was calculated for the select minority. Then, sensitivity and specificity of the silent majority were recalculated according to the Diamond criteria.Prevalence of coronary artery disease (32% versus 80%, p = 0.0001) and peak O2 consumption achieved in exercise tests (watts, exercise duration) were lower in women. The probability of positive results of 99mTc-MIBI SPECT also was lower in women (34% versus 65%). The sensitivity of 99mTc-MIBI SPECT in women of the select minority was lower (85% versus 93%, p = 0.01), whereas there was no significant difference for specificity (91% versus 89%). After correcting the results for the silent majority, there were no significant differences in sensitivity (87% versus 88%) and specificity (91% versus 96%) between women and men. These results were not different for patients who achieved maximum predicted heart rates during stress testing (without dipyridamole administration).The sensitivity of 99mTc-MIBI myocardial SPECT in women was lower than in men when only the select minority was considered. When the silent majority was considered (correction of selection bias) sensitivity and specificity results did not differ significantly between the sexes.
6. Postsurgical cerebral perfusion changes in idiopathic normal pressure hydrocephalus: A statistical parametric mapping study of SPECT images
- Author
-
Mataró, M., Poca, M. A., Salgado-Pineda, P., Joan Castell-Conesa, Sahuquillo, J., Díez-Castro, M. J., Aguadé-Bruix, S., Vendrell, P., Del Mar Matarín, M., and Junqué, C.
- Subjects
sense organs ,skin and connective tissue diseases - Abstract
Our goal was to study cerebral blood flow (CBF) changes after surgery in a group of 15 patients with idiopathic normal pressure hydrocephalus (NPH).
7. The valve uptake index: improving assessment of prosthetic valve endocarditis and updating [18F]FDG PET/CT(A) imaging criteria
- Author
-
Albert Roque, María N Pizzi, Nuria Fernández-Hidalgo, Guillermo Romero-Farina, Gemma Burcet, José Luis Reyes-Juarez, Carina Espinet, Joan Castell-Conesa, Manuel Escobar, Ignacio Ferreira-González, Santiago Aguadé-Bruix, Hug Cuellar-Calabria, Institut Català de la Salut, [Roque A, Burcet G, Reyes-Juarez JL, Cuellar-Calabria H] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. IDI (Institut de Diagnòstic per la Imatge), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Pizzi MN] Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomedica en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. [Fernández-Hidalgo N] Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Romero-Farina G] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Espinet C, Castell-Conesa J] IDI (Institut de Diagnòstic per la Imatge), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Escobar M] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. IDI (Institut de Diagnòstic per la Imatge), Barcelona, Spain. [Ferreira-González I] Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBER de Epidemiologıa y Salud Pública (CIBERESP), Madrid, Spain. [Aguadé-Bruix S] Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomedica en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. Servei de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Endocarditis bacteriana - Imatgeria ,Pròtesis valvulars cardíaques ,Prosthesis-Related Infections ,Endocarditis ,infecciones bacterianas y micosis::infección::infecciones relacionadas con prótesis [ENFERMEDADES] ,diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::interpretación de imágenes asistida por ordenador::tomografía computarizada por rayos X::angiografía por tomografía computarizada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Otros calificadores::Otros calificadores::/diagnóstico por imagen [Otros calificadores] ,General Medicine ,Endocarditis, Bacterial ,Fluorodeoxyglucose F18 ,Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Image Interpretation, Computer-Assisted::Tomography, X-Ray Computed::Computed Tomography Angiography [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Heart Valve Prosthesis ,Positron Emission Tomography Computed Tomography ,Cardiovascular Diseases::Heart Diseases::Endocarditis [DISEASES] ,Bacterial Infections and Mycoses::Infection::Prosthesis-Related Infections [DISEASES] ,Humans ,Radiology, Nuclear Medicine and imaging ,Tomografia per emissió de positrons ,enfermedades cardiovasculares::enfermedades cardíacas::endocarditis [ENFERMEDADES] ,Radiopharmaceuticals ,Cardiology and Cardiovascular Medicine ,Other subheadings::Other subheadings::/diagnostic imaging [Other subheadings] ,Retrospective Studies - Abstract
Aims Diagnosis of prosthetic valve endocarditis (PVE) by positron emission computed tomography angiography (PET/CTA) is based on visual and quantitative morpho-metabolic features. However, the fluorodeoxyglucose (FDG) uptake pattern can be sometimes visually unclear and susceptible to subjectivity. This study aimed to validate a new parameter, the valve uptake index [VUI, maximum standardized uptake value (SUVmax)−mean standardized uptake value (SUVmean)/SUVmax], designed to provide a more objective indication of the distribution of metabolic activity. Secondly, to re-evaluate the utility of traditionally used PVE imaging criteria and determine the potential value of adding the VUI in the diagnostic algorithm of PVE. Methods and results Retrospective analysis of 122 patients (135 prosthetic valves) admitted for suspicion of endocarditis, with a conclusive diagnosis of definite (N = 57) or rejected (N = 65) PVE, and who had undergone a cardiac PET/CTA scan as part of the diagnostic evaluation. We measured the VUI and recorded the SUVmax, SUVratio, uptake pattern, and the presence of endocarditis-related anatomic lesions. The VUI, SUVmax, and SUVratio values were 0.54 ± 0.1 vs. 0.36 ± 0.08, 7.68 ± 3.07 vs. 3.72 ± 1.11, and 4.28 ± 1.93 vs. 2.16 ± 0.95 in the ‘definite’ PVE group vs. the ‘rejected’ group, respectively (mean ± SD; P < 0.001). A cut-off value of VUI > 0.45 showed a sensitivity, specificity, and diagnostic accuracy for PVE of 85%, 88%, and 86.7% and increased diagnostic ability for confirming endocarditis when combined with the standard diagnostic criteria. Conclusions The VUI demonstrated good diagnostic accuracy for PVE, even increasing the diagnostic power of the traditionally used morphometabolic parameters, which also confirmed their own diagnostic performance. More research is needed to assess whether the integration of the VUI into the PVE diagnostic algorithm may clarify doubtful cases and thus improve the diagnostic yield of PET/CTA.
- Published
- 2021
8. Identification of Myocardial Insulin Resistance by Using Liver Tests: A Simple Approach for Clinical Practice
- Author
-
José Raúl Herance, Queralt Martín-Saladich, Mayra Alejandra Velásquez, Cristina Hernandez, Carolina Aparicio, Clara Ramirez-Serra, Roser Ferrer, Marina Giralt-Arnaiz, Miguel Ángel González-Ballester, Juan M. Pericàs, Joan Castell-Conesa, Santiago Aguadé-Bruix, Rafael Simó, Institut Català de la Salut, [Herance JR] Grup de Recerca d’Imatge Mèdica Molecular, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat Docent de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBERBBN, Instituto de Salud Carlos III, Madrid, Spain. [Martín-Saladich Q] Grup de Recerca d’Imatge Mèdica Molecular, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat Docent de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. BCN Medtech Group, Information and Communication Technologies Department, Pompeu Fabra University, Barcelona, Spain. [Velásquez MA] Grup de Recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Endocrinologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Hernandez C, Simó R] Grup de Recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Endocrinologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBERDEM, Instituto de Salud Carlos III, Madrid, Spain. [Aparicio C, Castell-Conesa J, Aguadé-Bruix S] Grup de Recerca d’Imatge Mèdica Molecular, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat Docent de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Ramirez-Serra C, Ferrer R, Giralt-Arnaiz M] Grup de Recerca de Bioquímica Clínica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Àrea de Core Facilities, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [González-Ballester MÁ] BCN Medtech Group, Information and Communication Technologies Department, Pompeu Fabra University, Barcelona, Spain. [Pericàs JM] Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat Hepàtica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBEREHD, Instituto de Salud Carlos III, Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
cardiovascular risk ,enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::diabetes mellitus::diabetes mellitus tipo II [ENFERMEDADES] ,Miocardi - Malalties ,Diabetis no-insulinodependent ,Catalysis ,Inorganic Chemistry ,Positron Emission Tomography Computed Tomography ,Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperinsulinism::Insulin Resistance [DISEASES] ,Humans ,Physical and Theoretical Chemistry ,Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Image Interpretation, Computer-Assisted::Tomography, Emission-Computed::Positron-Emission Tomography::Positron Emission Tomography Computed Tomography [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Molecular Biology ,Transaminases ,Spectroscopy ,Insulinoresistència ,enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::hiperinsulinismo::resistencia a la insulina [ENFERMEDADES] ,type 2 diabetes ,myocardial insulin resistance ,non-alcoholic fatty liver disease ,Myocardium ,Cardiovascular System::Heart::Myocardium [ANATOMY] ,Organic Chemistry ,Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus, Type 2 [DISEASES] ,General Medicine ,Fibrosis ,Computer Science Applications ,Diabetes Mellitus, Type 2 ,Liver ,sistema cardiovascular::corazón::miocardio [ANATOMÍA] ,Tomografia per emissió de positrons ,Insulin Resistance ,diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::interpretación de imágenes asistida por ordenador::tomografía computarizada radioisotópica::tomografía por emisión de positrones::tomografía por emisión de positrones-tomografía computarizada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] - Abstract
Cardiovascular risk; Myocardial insulin resistance; Non-alcoholic fatty liver disease Riesgo cardiovascular; Resistencia a la insulina del miocardio; Enfermedad del higado graso no alcoholico Risc cardiovascular; Resistència a la insulina del miocardi; Malaltia del fetge gras no alcohòlic Background: We report that myocardial insulin resistance (mIR) occurs in around 60% of patients with type 2 diabetes (T2D) and was associated with higher cardiovascular risk in comparison with patients with insulin-sensitive myocardium (mIS). These two phenotypes (mIR vs. mIS) can only be assessed using time-consuming and expensive methods. The aim of the present study is to search a simple and reliable surrogate to identify both phenotypes. Methods: Forty-seven patients with T2D underwent myocardial [18F]FDG PET/CT at baseline and after a hyperinsulinemic–euglycemic clamp (HEC) to determine mIR were prospectively recruited. Biochemical assessments were performed before and after the HEC. Baseline hepatic steatosis index and index of hepatic fibrosis (FIB-4) were calculated. Furthermore, liver stiffness measurement was performed using transient elastography. Results: The best model to predict the presence of mIR was the combination of transaminases, protein levels, FIB-4 score and HOMA (AUC = 0.95; sensibility: 0.81; specificity: 0.95). We observed significantly higher levels of fibrosis in patients with mIR than in those with mIS (p = 0.034). In addition, we found that patients with mIR presented a reduced glucose uptake by the liver in comparison with patients with mIS. Conclusions: The combination of HOMA, protein, transaminases and FIB-4 is a simple and reliable tool for identifying mIR in patients with T2D. This information will be useful to improve the stratification of cardiovascular risk in T2D. This work was supported by the Carlos III Health Institute and the European Regional Development Fund (PI16/02064, PI20/01588) and the Agency for Management of University and Research Grants (AGAUR) of Catalonia (2017SGR1303).
- Published
- 2022
- Full Text
- View/download PDF
9. Planning the Follow-Up of Patients with Stable Chronic Coronary Artery Disease
- Author
-
Santiago Aguadé-Bruix, Guillermo Romero-Farina, Institut Català de la Salut, [Romero-Farina G] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBERCV, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Aguadé-Bruix S] Servei de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBERCV, Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Medicine (General) ,medicine.medical_specialty ,Cross-sectional study ,Clinical Biochemistry ,planning the follow-up ,Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics::Epidemiologic Studies::Cohort Studies::Follow-Up Studies [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Review ,Disease ,cross-sectional analysis ,Coronary artery disease ,R5-920 ,Clinical history ,Economic cost ,Health care ,medicine ,Intensive care medicine ,Other subheadings::Other subheadings::/diagnostic imaging [Other subheadings] ,enfermedades cardiovasculares [ENFERMEDADES] ,Cause of death ,Cardiovascular Diseases [DISEASES] ,Imatgeria per al diagnòstic - Tècniques digitals ,business.industry ,Otros calificadores::Otros calificadores::/diagnóstico por imagen [Otros calificadores] ,longitudinal analysis ,medicine.disease ,técnicas de investigación::métodos epidemiológicos::características de los estudios epidemiológicos::estudios epidemiológicos::estudios de cohortes::estudios de seguimiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Sistema cardiovascular - Malalties - Imatgeria ,chronic coronary artery disease ,Heart failure ,business - Abstract
Enfermedad arterial coronaria crónica; Análisis longitudinal; Planificar el seguimiento Malaltia arterial coronària crònica; Anàlisi longitudinal; Planificar el seguiment Chronic coronary artery disease; Longitudinal analysis; Planning the follow-up Cardiovascular disease remains the leading cause of death among Europeans, Americans, and around the world. In addition, the prevalence of coronary artery disease (CAD) is increasing, with the highest number of hospital visits, hospital readmissions for patients with decompensated heart failure, and a high economic cost. It is, therefore, a priority to try to plan the follow-up of patients with stable chronic CAD (scCAD) in relation to the published data, experience, and new technology that we have today. Planning the follow-up of patients with scCAD goes beyond the information provided by clinical management guidelines. It requires understanding the importance of a cross-sectional and longitudinal analysis in the clinical history of scCAD, because it has an impact on the cost of healthcare in relation to mortality, economic factors, and the burden of medical consultations. Using the data provided in this work facilitates and standardizes the clinical follow-up of patients with scCAD, and following the marked line makes the work for the clinical physician much easier, by including most clinical possibilities and actions to consider. The follow-up intervals vary according to the clinical situation of each patient and can be highly variable. In addition, the ability to properly study patients with imaging techniques, to stratify at different levels of risk, helps plan the intervals during follow-up. Given the complexity of coronary artery disease and the diversity of clinical cases, more studies are required in the future focused on improving the planning of follow-up for patients with scCAD. The perspective and future direction are related to the valuable utility of integrated imaging techniques in clinical follow-up. This research received no external funding.
- Published
- 2021
- Full Text
- View/download PDF
10. Diabetic retinopathy as an independent predictor of subclinical cardiovascular disease: baseline results of the PRECISED study
- Author
-
Simó Canonge, Rafael, Bañeras, Jordi, Hernández, Cristina, Rodríguez-Palomares, José, Valente, Filipa, Gutierrez, Laura, González-Alujas, Teresa, Ferreira-Gonzalez, Ignacio, Aguadé-Bruix, Santiago, Montaner, Joan, Seron, Daniel, Genescà, J., Boixadera Espax, Anna, García Arumí, José, Planas, Alejandra, Simó-Servat, Olga, García-Dorado, David, Universitat Autònoma de Barcelona, [Planas A] Grup de Recerca en Diabetis i Metabolisme, Vall d'Hebron Institut de Recerca, Barcelona, Spain. Servei d’Endocrinologia, Hospital Universitari Vall d’Hebron, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Simó R, Hernández C, Simó-Servat O] Grup de Diabetis i Metabolisme, Vall d'Hebron Institut de Recerca, Barcelona, Spain. Servei d’Endocrinologia, Hospital Universitari Vall d’Hebron, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. [Bañeras J, Rodríguez-Palomares J, Valente F, Gutierrez L, González-Alujas T, Ferreira I, García-Dorado D] Grup de Recerca en Malalties Cardiovasculars, Vall d'Hebron Institut de Recerca, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBER CV), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. [Aguadé-Bruix S] Àrea de Recerca Mèdica i Metabòlica, Vall d'Hebron Institut de Recerca, Barcelona, Spain. Servei de Medicina Nuclear, Hospital Universitari Vall d’Hebron, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Montaner J] Recerca en Malalties Neurovasculars, Vall d'Hebron Institut de Recerca, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Seron D] Recerca en Nefrologia, Vall d'Hebron Institut de Recerca, Barcelona, Spain. Servei de Nefrologia, Vall d'Hebron Hospital, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. Red de Investigación Renal, (REDinREN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. [Genescà J] Recerca en Malalties Hepàtiques, Vall d'Hebron Institut de Recerca, Barcelona, Spain. Servei de Medicina Interna, Vall d'Hebron Hospital, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas, (CIBEREHD), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. [Boixadera A, García-Arumí J] Recerca en Oftalmologia, Vall d'Hebron Institut de Recerca, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain., and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Male ,cardiovacsular disease(s) ,enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::diabetes mellitus::diabetes mellitus tipo II [ENFERMEDADES] ,Endocrinology, Diabetes and Metabolism ,Type 2 diabetes ,Coronary Angiography ,Sistema cardiovascular - Malalties ,Carotid Intima-Media Thickness ,Diabetis no-insulinodependent ,Coronary artery disease ,0302 clinical medicine ,Risk Factors ,Prospective Studies ,030212 general & internal medicine ,Subclinical infection ,Cardiovascular Diseases [DISEASES] ,Incidence ,Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus, Type 2 [DISEASES] ,Diabetic retinopathy ,Middle Aged ,Prognosis ,Cardiovascular Diseases ,Cardiology ,Female ,type 2 diabetes ,medicine.symptom ,enfermedades cardiovasculares::enfermedades vasculares::angiopatías diabéticas::retinopatía diabética [ENFERMEDADES] ,Retinopathy ,Cardiovascular and Metabolic Risk ,medicine.medical_specialty ,030209 endocrinology & metabolism ,Retinography ,Asymptomatic ,03 medical and health sciences ,Cardiovascular Diseases::Vascular Diseases::Diabetic Angiopathies::Diabetic Retinopathy [DISEASES] ,Internal medicine ,Diabetes mellitus ,retinopathy ,medicine ,Humans ,cardiovascular diseases ,Aged ,enfermedades cardiovasculares [ENFERMEDADES] ,Diabetic Retinopathy ,business.industry ,medicine.disease ,Diabetes Mellitus, Type 2 ,Spain ,Case-Control Studies ,Retinopatia diabètica ,Tomography, X-Ray Computed ,business ,Biomarkers ,Follow-Up Studies - Abstract
Type 2 diabetes; Diabetic retinopathy; Subclinical cardiovascular disease Diabetis tipus 2; Retinopatia diabètica; Malalties cardiovasculars subclíniques Diabetes tipo 2; Retinopatía diabética; Enfermedades cardiovasculares subclínicas Objective Detection of subclinical cardiovascular disease (CVD) has significant impact on the management of type 2 diabetes. We examined whether the assessment of diabetic retinopathy (DR) is useful for identifying patients at a higher risk of having silent CVD. Research design and methods Prospective case–control study comprising 200 type 2 diabetic subjects without history of clinical CVD and 60 age-matched non-diabetic subjects. The presence of subclinical CVD was examined using two parameters: (1) calcium coronary score (CACs); (2) composite of CACs >400 UA, carotid plaque ≥3 mm, carotid intima–media thickness ratio >1, or the presence of ECG changes suggestive of previous asymptomatic myocardial infarction. In addition, coronary angio-CT was performed. DR was assessed by slit-lamp biomicroscopy and retinography. Results Type 2 diabetic subjects presented higher CACs than non-diabetic control subjects (p400 (area under the receiver operating characteristic curve (AUROC) 0.76). In addition, an inverse relationship was observed between the degree of DR and CACs
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.